Therapeutic role of fluconazole in immunocompetent patients with pulmonary cryptococcosis: A case report

Abstract

The present investigation examines the potential for customized treatment of pulmonary cryptococcosis using fluconazole in an immunocompetent individual. Therapeutic drug monitoring (TDM) was utilized throughout treatment to assess fluconazole levels. Research indicated that the MIC₉₀ for cryptococcus in China is around 8 mg/L. We evaluated the area under the curve (AUC) relative to the minimal inhibitory concentration (MIC), focusing on the AUC from 0 to 24 h (AUC0–24 h/MIC). Fluconazole's dosage was adjusted according to pharmacokinetics/pharmacodynamics (PK/PD) principles to enhance therapeutic efficacy. Post-treatment evaluation showed marked improvement in the patient's condition, with lesions exhibiting partial absorption.